1Q23 Business Results

TruximaⓇ ✓ Started direct sales in the EU since 2H22, revenue has recovered by the active bid participation ✓ Maintained stable M/S in the US markets with optimal price strategy M/S of TruximaⓇ in Europe 40% 39% 38% 37% 36% 36% 31% 29% 24% 22% 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 22.2Q MabtheraⓇ TruximaⓇ C Biosimilar Note: The market share is based on volume Source: IQVIA M/S of TruximaⓇ in the US 37% 30% 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q 3Q 4Q 23.1Q TruximaⓇ D Biosimilar 32% 29% 4Q 44 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q 2Q 3Q 4Q 23.1Q TruximaⓇ D Biosimilar 출처 : Symphony Health Investor Relations 2023 9 1Q23 Business Results Key Products Plan & Vision Appendix

View entire presentation